Long-term combination chemotherapy using eribulin and trastuzumab for three patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

The combination chemotherapy regimen of eribulin (ERI) and trastuzumab (TRA)—the ERI-TRA regimen—has been shown to be highly tolerable for patients with recurrent or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, no sufficient clinical evidence is availab...

Descripción completa

Detalles Bibliográficos
Autores principales: Saeki, Toshiaki, Araki, Kazuhiro, Shimada, Ken, Shigekawa, Takashi, Nakayama, Hirofumi, Segawa, Yoshihiko, Mukai, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498262/
https://www.ncbi.nlm.nih.gov/pubmed/31149450
http://dx.doi.org/10.1007/s13691-016-0253-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498262/
https://www.ncbi.nlm.nih.gov/pubmed/31149450
http://dx.doi.org/10.1007/s13691-016-0253-y

Ejemplares similares